From Benchtop to Bedside: A Review of Oncolytic Virotherapy

Oncolytic viruses (OVs) demonstrate the ability to replicate selectively in cancer cells, resulting in antitumor effects by a variety of mechanisms, including direct cell lysis and indirect cell death through immune-mediate host responses. Although the mechanisms of action of OVs are still not fully...

Full description

Bibliographic Details
Main Authors:	Audrey H. Choi, Michael P. O’Leary, Yuman Fong, Nanhai G. Chen
Format:	Article
Language:	English
Published:	MDPI AG 2016-08-01
Series:	Biomedicines
Subjects:	oncolytic viruses immunotherapy virotherapy
Online Access:	http://www.mdpi.com/2227-9059/4/3/18

id	doaj-cfff1cd7d53e4d91ab9ae27cbf4dda2a
record_format	Article
spelling	doaj-cfff1cd7d53e4d91ab9ae27cbf4dda2a2020-11-24T21:05:52ZengMDPI AGBiomedicines2227-90592016-08-01431810.3390/biomedicines4030018biomedicines4030018From Benchtop to Bedside: A Review of Oncolytic VirotherapyAudrey H. Choi0Michael P. O’Leary1Yuman Fong2Nanhai G. Chen3Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USAOncolytic viruses (OVs) demonstrate the ability to replicate selectively in cancer cells, resulting in antitumor effects by a variety of mechanisms, including direct cell lysis and indirect cell death through immune-mediate host responses. Although the mechanisms of action of OVs are still not fully understood, major advances have been made in our understanding of how OVs function and interact with the host immune system, resulting in the recent FDA approval of the first OV for cancer therapy in the USA. This review provides an overview of the history of OVs, their selectivity for cancer cells, and their multifaceted mechanism of antitumor action, as well as strategies employed to augment selectivity and efficacy of OVs. OVs in combination with standard cancer therapies are also discussed, as well as a review of ongoing human clinical trials.http://www.mdpi.com/2227-9059/4/3/18oncolytic virusesimmunotherapyvirotherapy
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Audrey H. Choi Michael P. O’Leary Yuman Fong Nanhai G. Chen
spellingShingle	Audrey H. Choi Michael P. O’Leary Yuman Fong Nanhai G. Chen From Benchtop to Bedside: A Review of Oncolytic Virotherapy Biomedicines oncolytic viruses immunotherapy virotherapy
author_facet	Audrey H. Choi Michael P. O’Leary Yuman Fong Nanhai G. Chen
author_sort	Audrey H. Choi
title	From Benchtop to Bedside: A Review of Oncolytic Virotherapy
title_short	From Benchtop to Bedside: A Review of Oncolytic Virotherapy
title_full	From Benchtop to Bedside: A Review of Oncolytic Virotherapy
title_fullStr	From Benchtop to Bedside: A Review of Oncolytic Virotherapy
title_full_unstemmed	From Benchtop to Bedside: A Review of Oncolytic Virotherapy
title_sort	from benchtop to bedside: a review of oncolytic virotherapy
publisher	MDPI AG
series	Biomedicines
issn	2227-9059
publishDate	2016-08-01
description	Oncolytic viruses (OVs) demonstrate the ability to replicate selectively in cancer cells, resulting in antitumor effects by a variety of mechanisms, including direct cell lysis and indirect cell death through immune-mediate host responses. Although the mechanisms of action of OVs are still not fully understood, major advances have been made in our understanding of how OVs function and interact with the host immune system, resulting in the recent FDA approval of the first OV for cancer therapy in the USA. This review provides an overview of the history of OVs, their selectivity for cancer cells, and their multifaceted mechanism of antitumor action, as well as strategies employed to augment selectivity and efficacy of OVs. OVs in combination with standard cancer therapies are also discussed, as well as a review of ongoing human clinical trials.
topic	oncolytic viruses immunotherapy virotherapy
url	http://www.mdpi.com/2227-9059/4/3/18
work_keys_str_mv	AT audreyhchoi frombenchtoptobedsideareviewofoncolyticvirotherapy AT michaelpoleary frombenchtoptobedsideareviewofoncolyticvirotherapy AT yumanfong frombenchtoptobedsideareviewofoncolyticvirotherapy AT nanhaigchen frombenchtoptobedsideareviewofoncolyticvirotherapy
_version_	1716767608275992576

From Benchtop to Bedside: A Review of Oncolytic Virotherapy

Similar Items